Wall Street Zen Downgrades Omeros (NASDAQ:OMER) to Sell

Omeros (NASDAQ:OMER - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Friday.

A number of other equities research analysts have also recently issued reports on OMER. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research note on Friday, May 16th. D. Boral Capital restated a "buy" rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Omeros presently has an average rating of "Moderate Buy" and an average price target of $22.50.

Omeros Price Performance

OMER stock remained flat at $3.77 during midday trading on Friday. 701,847 shares of the company's stock were exchanged, compared to its average volume of 683,614. The company's 50-day moving average is $5.45 and its 200-day moving average is $7.96. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60. The company has a market cap of $220.90 million, a P/E ratio of -1.63 and a beta of 2.20.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). As a group, analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

Institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Omeros by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 1,110 shares during the period. Truvestments Capital LLC boosted its position in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the period. Tower Research Capital LLC TRC boosted its position in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 1,972 shares during the period. Deutsche Bank AG boosted its position in Omeros by 4.9% during the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock valued at $345,000 after buying an additional 1,973 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in Omeros by 2.0% during the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock valued at $1,190,000 after buying an additional 2,317 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.